8-KItem 2.02 · Results of OperationsItem 9.01 · Financial Statements
AbbVie raises 2026 guidance as third-quarter revenue rises 10.3%
Filed with the SEC on · Summarized by InvestorsBot
AbbVie reported third-quarter 2026 revenue of $17.404 billion, up 10.3% year over year, with adjusted diluted EPS of $3.82 and GAAP diluted EPS of $2.37. Growth was led by Skyrizi and Rinvoq, while Humira revenue fell 31.2%; AbbVie also completed its Apogee Therapeutics acquisition and raised 2026 adjusted EPS guidance to $13.95-$13.99 from $13.76-$13.96. The company will increase its quarterly dividend 5.2% to $1.82 per share beginning with the dividend payable February 16, 2027.